RCS - Agronomics Limited - Portfolio Company Presentation Series – Onego Bio

AgronomicsAnnouncement

10/04/2024 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240410:nRSJ0175Ka&default-theme=true

RNS Number : 0175K  Agronomics Limited  10 April 2024

 

10 April 2024

 Agronomics Limited

("Agronomics" or the "Company")

Portfolio Company Presentation Series - Onego Bio Limited

Agronomics (LSE: ANIC), a leading listed company in the field of cellular
agriculture, is pleased to announce that it will be hosting the second
presentation in its Capital Markets portfolio series.

The Agronomics' Capital Markets Investor Presentation Series comprises
individual presentations from industry-leading companies in the cell culture
and precision fermentation sector within the Agronomics portfolio. For each
presentation, the portfolio company's management team will provide in-depth
insights into the purpose, market demand, technical milestones, and growth
strategy of the company, together with a Question & Answer session at the
end of the presentation. Agronomics expects to hold, on average, a
presentation every eight weeks.

The second presentation will include the senior management team at Onego Bio
Limited ("Onego Bio") on Wednesday, 24 April 2024 at 3:00 pm BST. Attendees
are able to register for the event using the following link:

https://us02web.zoom.us/webinar/register/WN_UwXJAGhoR0Cr66Kh_LOP1w#/registration
(https://us02web.zoom.us/webinar/register/WN_UwXJAGhoR0Cr66Kh_LOP1w#/registration)

After registering, attendees will receive a confirmation email containing
information about joining the webinar.

Onego Bio is a US-Finnish food-biotech company revolutionizing the food system
by harnessing the power of precision fermentation to manufacture real egg
protein which is entirely animal-free. Their product, Bioalbumen®, sets a new
standard for sustainable protein with identical taste and nutrition, superior
functional properties, and a 90% plus smaller environmental footprint when
compared to eggs from chickens.

Onego Bio recently announced that it has successfully raised €36.5 million
in its Series A funding round to continue scaling and optimising its
production processes and productivity, finance its work with its contract
manufacturing partners, and prepare for US Food and Drug Administration
("FDA") filing for regulatory approval in the United States. Onego Bio is on
track to receive self-affirmed "Generally Recognized as Safe" status for
Bioalbumen® this year, with a no-objections letter expected from the FDA in
2025. As a US-Finnish company, Onego Bio plans to first launch in North
America, followed by expansion in Europe, South America, and Asia.

About Onego Bio:

Onego Bio is a US-Finnish food-biotech company revolutionizing the food system
by harnessing the power of precision fermentation to manufacture real egg
protein entirely animal-free. Their ingredient, Bioalbumen®, sets a new
standard for sustainable protein with identical taste and nutrition, superior
functional properties and over 90% smaller environmental footprint compared to
eggs from chickens. Onego's highly productive and scalable technology caters
to the needs of the food industry searching for stable, sustainable functional
ingredients. As a game-changer in the field, the company was selected the
Winner of Fast Company's 2023 World Changing Ideas awards and is a co-founder
of two industry associations: Precision Fermentation Alliance and Food
Fermentation Europe. Learn more at www.onego.bio (http://www.onego.bio) .

 

About Bioalbumen®

Bioalbumen® is a bioidentical protein to the major protein in chicken egg
white, ovalbumin. Nutritionally complete, Onego's egg protein contains all
essential amino acids, has the highest possible protein digestibility score
PDCAAS of 1.0, and delivers a whopping >90 g protein per 100 g. With a
clean neutral flavor and superior functional properties, Bioalbumen® is an
ideal industrial ingredient for replacing eggs and enhancing the texture,
taste, and performance of a wide range of applications across the food
industry. Onego currently collaborates with over twenty-five well-known CPG
companies, integrating Bioalbumen® into their innovation pipeline for a wide
range of products, including baked goods, confectionery, snacks, sauces,
pasta, meat alternatives, and more.

 

About Agronomics

Agronomics is a leading listed company focussing on investment opportunities
within the field of cellular agriculture. The Company has established a
portfolio of over twenty companies in this rapidly advancing sector. It seeks
to invest in companies owning technologies with defensible intellectual
property that offer new ways of producing food and ingredients with a focus on
products historically derived from animals. These technologies are driving a
major disruption in agriculture, offering solutions to improve sustainability
and address human health, food security, and animal welfare. A full list of
Agronomics' portfolio companies is available at https://agronomics.im/
(https://agronomics.im/) .

 

For further information please contact:

 Agronomics           Beaumont              Canaccord Genuity Limited  Cavendish Capital Markets Limited  Peterhouse Capital    SEC Newgate

 Limited              Cornish Limited                                                                     Limited
 The Company          Nomad                 Joint Broker               Joint Broker                       Joint Broker          Public Relations
 Jim Mellon           Roland Cornish        Andrew Potts               Giles Balleny                      Lucy Williams         Bob Huxford

 Anthony Hughes
 Denham Eke           James Biddle          Harry Pardoe               Michael Johnson                    Charles Goodfellow

                                            Alex Aylen                 Charlie Combe
 +44 (0) 1624 639396  +44 (0) 207 628 3396  +44 (0) 207 523 8000       +44 (0) 207 397 8900               +44 (0) 207 469 0936  agronomics@secnewgate.co.uk

 info@agronomics.im

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUPUCUPCURU